Drug Pricing: List vs Net Price and Gross-to-Net Gap

Every biotech launch headline quotes a price: $180,000 a year, $425,000 a course, $3.2 million a dose. Every investor reads that number and assumes it is revenue. It is not. Between the list price and the net revenue the company actually books sits the gross-to-net waterfall: PBMs, rebates, 340B, Medicaid, and patient assistance that together shave 30% to 60% off the headline. The gap is the difference between an FDA-approved drug and a commercially successful one.

The one-sentence answer: read the net price disclosure on the earnings call, not the list price in the press release. Here is the waterfall, layer by layer.

Step 1: Start at the list price

The list price is the sticker price, the number in the launch press release. Almost nobody actually pays it. It exists because rebates and discounts are calculated as percentages of it, so it is the anchor for negotiation, not the revenue line. In 2025, total gross-to-net reductions across U.S. brand-name drugs reached $416 billion, according to Drug Channels Institute.

Step 2: Subtract statutory discounts

The first mandatory haircuts come from law, not negotiation. Medicaid best-price rules require manufacturers to give state Medicaid programs their lowest price. The 340B program forces steep discounts, often 25% to 50%, on drugs sold to safety-net hospitals and clinics. Neither is optional.

Step 3: Subtract contractual rebates to PBMs

This is the biggest layer and the one that decides commercial fate. A pharmacy benefit manager, or PBM, negotiates rebates on behalf of insurers and employers in exchange for putting a drug on formulary, the list of covered drugs. Three PBMs, CVS Caremark, Express Scripts, and OptumRx, process about 80% of U.S. prescription claims. That concentration is the pricing power.

A high list price with a big rebate can beat a low list price with a weak formulary position. Bristol Myers Squibb disclosed that its average discount from list widened to roughly 53% in 2025, up from about 49% in 2024. More than half the list price never reaches the company.

Step 4: Subtract channel and wholesaler discounts

Distributors and pharmacies take their cut. These are smaller, usually low single digits, but they compound on top of everything else.

Step 5: Subtract patient assistance and copay support

Manufacturers pay patient assistance programs and copay cards to keep patients on expensive drugs. It is a real cost that reduces net revenue, and it spikes during a launch when the company is trying to build adoption.

Step 6: What is left is net price

Net price is what the company actually books per unit. It is the number that matters for revenue, and it is the number management discloses as net price realization or gross-to-net percentage on earnings calls. The difference between list and net is the gross-to-net gap.

Run the waterfall on a real headline. A drug priced at $200,000 a year loses roughly 20% to Medicaid and 340B statutory discounts, then another 35% to PBM rebates to hold formulary position, then a few points to wholesalers and copay cards. Net price lands around $90,000. The company booked less than half the sticker, and every one of those layers was on the table before the first script was written.

Why the gap varies by indication

The gap tracks competition and formulary bargaining power. Mass-market primary care drugs face the heaviest discounting. Insulin is the extreme: one JAMA study of 602 branded drugs found insulin list prices rose 262% from 2007 to 2018 while net prices rose only 51%. GLP-1 net prices fell more than 34% in the first three quarters of 2025 even as total spending rose on volume.

Orphan drugs and gene therapies sit at the other end of the spectrum. A one-time cure for a rare disease has no direct competitor and a tiny patient pool, so the gross-to-net gap is narrower. But the price is so high, in the millions per dose, that a different problem appears: whether any payer will actually cover it. The orphan drug pricing guide and the gene therapy pricing math cover those cases.

How the IRA changes the math

The Inflation Reduction Act lets Medicare negotiate prices on high-revenue drugs, which compresses the net price directly and shrinks the spread between list and net. For a guide on how that reshapes biotech valuations, read the IRA pricing piece.

Reading the launch on the earnings call

Three figures tell you whether a launch is working. Net price realization, the average net price as a percentage of list. Gross-to-net percentage, the discount the company is absorbing. And launch trajectory, whether scripts and revenue are ramping or stalling. The earnings guide breaks down the five numbers that matter.

Where to find the number: the quarterly earnings press release and the 10-Q filing on SEC EDGAR. Search the management discussion for “gross-to-net” or “net price realization.” Some companies bury it; the ones with nothing to hide put it in the press release headline. If management will not disclose it, treat that silence as a data point.

Common mistakes

Reading the list price as revenue. You bought the $180,000 headline and the company is booking $80,000 after rebates.

Ignoring the gross-to-net disclosure. If management does not disclose net price realization, that is a signal, not an oversight.

Assuming a high list price means high margins. A drug with a big rebate and a weak formulary position can be less profitable than a cheaper drug with better coverage.

Final checklist

• What is the list price, and what is the disclosed gross-to-net percentage?
• How steep are the PBM rebates, and is the drug on preferred formulary?
• Does the indication have deep discounting, or is it orphan and closer to full price?
• What does management disclose on net price realization and launch trajectory?
• Is the drug exposed to IRA Medicare negotiation?

The price tag on a launch press release is marketing, not revenue. Find the net price, and you will know within one earnings call whether an approval is turning into a business or a disappointment.